Top 10 global R&D institutes
To view this email as a web page, click here

Featured Story

After FDA rejection, Gilead's long-acting HIV med Sunlenca snags first global nod

Nearly six months after an FDA rejection, Gilead Sciences’ next-generation, long-acting HIV med lenacapavir has picked up its global-first approval in Europe. But the company still needs to find the first-in-class drug a proper combination partner after a high-profile Merck setback.

read more

Top Stories

Anthony Fauci, the face of the White House's COVID-19 response, is stepping down from public service in December

The country's foremost infectious disease expert's career has included over 50 years at the National Institutes of Health, including 38 years as director of the National Institute of Allergy and Infectious Diseases. He advised seven presidents' responses to pressing infectious disease threats but became a household name during the COVID-19 pandemic.

read more

The top 10 global R&D institutes of 2021

Advances in the biomedical industry are often a function of quality research produced at academic research institutions around the world. This year's list of top R&D outposts had a number of changes, namely the addition of more Chinese institutions.

read more

Elon Musk reportedly approached Neuralink competitor Synchron about potential deal: Reuters

If you can’t beat ‘em, join ‘em. Brain-computer interface developer Synchron has already begun implanting its own devices in a clinical trial, steps ahead of Elon Musk's Neuralink.

read more

Employer health costs set to rise 6.5% in 2023: Aon

This is more than double the 3% increase that employers saw in 2022 but far below the current inflation index, according to Aon.

read more

Insulet's Omnipod 5 insulin pump scores FDA nod for toddlers with Type 1 diabetes

Just a few weeks into the full-scale rollout of its Omnipod 5 insulin pump, Insulet has gotten the green light to expand the device’s reach even further.

read more

2 biotechs swoop into monkeypox scene with new R&D licensing pact

Lytic Solutions has circled in on NightHawk Biosciences’ monkeypox vaccine science, penning a licensing deal with the ultimate goal of developing a vaccine that will address a potential monkeypox pandemic.

read more

Takeda's dengue fever vaccine picks up first global nod in Indonesia

After a long road, Takeda's dengue fever vaccine has finally picked up its first global approval in Indonesia, where the dengue fever epidemic runs rampant. The approval was based on results of Takeda's phase 3 efficacy study, dubbed TIDES.

read more

Signify Health shares jump as Amazon, UnitedHealth reportedly among bidders for takeover deal

Signify Health shares jumped nearly 40% premarket Monday morning as reports surfaced that Amazon and UnitedHealth Group are both eyeing a bid for the home health technology and services provider.

read more

Novo Nordisk to explore obesity risk tests with Digbi Health pilot project

By working with Digbi and the startup’s digital screening offerings, the pilot will explore how a person’s genes, proteins, gut bacteria and lifestyle data can help predict whether they may have a high or low risk of obesity.

read more

Thermo Fisher kicks off production at giant plant in Tennessee, where it plans to hire more than 1,000

As part of its recent expansion surge, Thermo Fisher has identified single-use technology (SUT) manufacturing as an important area of focus. On Monday, when the Massachusetts-based manufacturer opened a $105 million plant in Lebanon, Tennessee, it became the company’s largest SUT site in its growing network.

read more

Ex-Takeda leader to provide steady hand as Tessa's CEO after C-suite churn

Former Takeda exec Thomas Willemsen will be taking the reins as Tessa Therapeutic’s new president and CEO as the CAR-T biotech gears up in anticipation of several clinical milestones.

read more

Teleflex snaps up surgical stapler maker Standard Bariatrics for $170M upfront

Standard Bariatrics’ Titan SGS system, which received an FDA clearance last year, is designed for use in weight loss procedures and can deliver a long, continuous line of staples in a single firing.

read more

Biden admin releases final surprise billing rule that updates dispute resolution process after legal setbacks

The Biden administration released Friday a final rule that updates the arbitration process providers and insurers can use to settle out-of-network billing disputes after the federal government suffered several legal setbacks to the No Surprises Act.

read more

Resources

eBook: Make the most out of hybrid conferences

Improve your congress competitive intelligence and cut down costs by 50%

Whitepaper: Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Whitepaper: The Hands-Free, Low-Volume, Microfluidic Elisa Alternative

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Whitepaper: Plan for scalable process liquid and buffer preparation

Set a solid foundation for successful scale-up of buffer preparation.

Whitepaper: End-to-end support for your asset's commercialization

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

Whitepaper: Genetic Insights for Biopharmaceuticals

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

Whitepaper: The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Article: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Whitepaper: Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Case Study: Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

Article: Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

eBook: Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Whitepaper: Catalent Pulmonary & Nasal Delivery Capabilities Sheet

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

On-Demand Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.